Showing results (171-180 of 276) with videos related to

Sort By:
Pageof 28
Plos One|February 7, 2022
Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancerFlorian Heitz, Sotirios Lakis, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
The Journal of Molecular Diagnostics : JMD|October 3, 2022
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic ProfilingCarsten Denkert, Marcel Romey, Brad Swedlund, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Breast Cancer Research and Treatment|November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyNadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Gynecologic Oncology|September 13, 2020
Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter studyHelmut Plett, Olga T Filippova, Annalisa Garbi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slidesFrederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancerAlejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Gynecologic Oncology|January 15, 2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trialMichel Fabbro, Kathleen N Moore, Anne Dørum, et al.
Pageof 28